Literature DB >> 17053180

Baicalein and 12/15-lipoxygenase in the ischemic brain.

Klaus van Leyen1, Hahn Young Kim, Seong-Ryong Lee, Guang Jin, Ken Arai, Eng H Lo.   

Abstract

BACKGROUND AND
PURPOSE: The natural product baicalein is a specific inhibitor of 12/15-lipoxygenase, but it also has antioxidant properties. The current study was designed to test if the neuroprotective properties of baicalein are related to its lipoxygenase inhibition.
METHODS: The presence of 12/15-lipoxygenase in the ischemic mouse brain was demonstrated by immunohistochemistry. A mouse model of transient middle cerebral artery occlusion was used to study lipoxygenase-dependent protection of the ischemic brain by baicalein. Rat primary neurons were subjected to oxidative stress in the presence or absence of baicalein.
RESULTS: In a mouse model of transient middle cerebral artery occlusion, 12/15-lipoxygenase is increased in the peri-infarct area surrounding the primary infarction, predominantly in neurons. Oxidative toxicity in primary rat neurons is reduced by baicalein. C57Bl6J mice are protected against transient focal ischemia by intraperitoneal injection of baicalein, and a similar degree of protection is seen in 12/15-lipoxygenase knockout mice compared with wild-type mice. In contrast, the 12/15-LOX knockout mice are not further protected by baicalein.
CONCLUSIONS: Baicalein protects against ischemia/reperfusion injury by inhibiting the 12/15-lipoxygenase pathway to neuronal cell death.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17053180     DOI: 10.1161/01.STR.0000249004.25444.a5

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  88 in total

Review 1.  Functional and pathological roles of the 12- and 15-lipoxygenases.

Authors:  Anca D Dobrian; David C Lieb; Banumathi K Cole; David A Taylor-Fishwick; Swarup K Chakrabarti; Jerry L Nadler
Journal:  Prog Lipid Res       Date:  2010-10-21       Impact factor: 16.195

Review 2.  Therapies targeting lipid peroxidation in traumatic brain injury.

Authors:  Tamil Selvan Anthonymuthu; Elizabeth Megan Kenny; Hülya Bayır
Journal:  Brain Res       Date:  2016-02-10       Impact factor: 3.252

Review 3.  Pathophysiology of glia in perinatal white matter injury.

Authors:  Stephen A Back; Paul A Rosenberg
Journal:  Glia       Date:  2014-03-31       Impact factor: 7.452

Review 4.  Therapeutic Potential of Baicalein in Alzheimer's Disease and Parkinson's Disease.

Authors:  Yanwei Li; Jinying Zhao; Christian Hölscher
Journal:  CNS Drugs       Date:  2017-08       Impact factor: 5.749

5.  Inflammation after stroke: mechanisms and therapeutic approaches.

Authors:  Muzamil Ahmad; Steven H Graham
Journal:  Transl Stroke Res       Date:  2010-06       Impact factor: 6.829

Review 6.  Intracellular zinc release, 12-lipoxygenase activation and MAPK dependent neuronal and oligodendroglial death.

Authors:  Yumin Zhang; Elias Aizenman; Donald B DeFranco; Paul A Rosenberg
Journal:  Mol Med       Date:  2007 Jul-Aug       Impact factor: 6.354

7.  12/15-Lipoxygenase deficiency protects mice from allergic airways inflammation and increases secretory IgA levels.

Authors:  Amanda R Hajek; Alexa R Lindley; Silvio Favoreto; Roderick Carter; Robert P Schleimer; Douglas A Kuperman
Journal:  J Allergy Clin Immunol       Date:  2008-08-09       Impact factor: 10.793

8.  Impact of 12/15-Lipoxygenase on Brain Injury After Subarachnoid Hemorrhage.

Authors:  Thomas Gaberel; Clément Gakuba; Yi Zheng; Matthieu Lépine; Eng H Lo; Klaus van Leyen
Journal:  Stroke       Date:  2019-02       Impact factor: 7.914

9.  A novel approach to screening for new neuroprotective compounds for the treatment of stroke.

Authors:  Pamela Maher; Karmen F Salgado; Justin A Zivin; Paul A Lapchak
Journal:  Brain Res       Date:  2007-08-09       Impact factor: 3.252

10.  Vitamin K prevents oxidative cell death by inhibiting activation of 12-lipoxygenase in developing oligodendrocytes.

Authors:  Jianrong Li; Hong Wang; Paul A Rosenberg
Journal:  J Neurosci Res       Date:  2009-07       Impact factor: 4.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.